Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

Amy J. Davidoff, Sheila Weiss Smith, Maria R. Baer, Xuehua Ke, Jason M. Bierenbaum, Franklin Hendrick, Diane L. Mcnally, Steven D. Gore

Research output: Contribution to journalArticlepeer-review

Abstract

Patient and physician characteristics associated with use of erythropoiesis-stimulating agents in myelodysplastic syndrome patients have not yet been described. Myelodysplastic syndrome patients diagnosed from 2001 to 2005 were identified from the Surveillance Epidemiology and End Results-Medicare database. Multivariate regressions examined the association between patient and physician characteristics and the probability of receiving any erythropoiesis-stimulating agents, and of receiving therapeutic-length (≥8 week) treatment episodes. Among the 6,588 myelodysplastic syndrome patients studied, 65% received erythropoiesis-stimulating agents. Use of erythropoiesis-stimulating agents was lower for blacks compared to whites (OR 0.78; 95% CI:0.61-0.99), single persons compared to married (OR 0.77; 95% CI:0.62-0.97), Medicaid recipients (OR 0.66; 95% CI:0.55-0.79), and those living in census tracts with lower educational attainment. Patients who did not consult a hematology-oncology specialist were less likely to receive erythropoiesis-stimulating agents. Specialist access, financial resources and mobility are key determinants of receipt of erythropoiesis-stimulating agents among myelodysplastic syndrome patients.

Original languageEnglish (US)
Pages (from-to)128-132
Number of pages5
JournalHaematologica
Volume97
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • Characteristics
  • Erythropoiesis-stimulating agent
  • Myelodys-plastic syndromes
  • Patient
  • Physician

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this